{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:16:04Z","timestamp":1782504964884,"version":"3.54.5"},"reference-count":94,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as possible into a condition of treatment-free remission (TFR). The Gruppo Italiano Malattie EMatologiche dell\u2019Adulto (GIMEMA; Italian Group for Hematologic Diseases of the Adult) CML Working Party (WP) has developed a project aimed at selecting the treatment policies that may increase the probability of TFR, taking into account 4 variables: the need for TFR, the tyrosine kinase inhibitors (TKIs), the characteristics of leukemia, and the patient. A Delphi-like method was used to reach a consensus among the representatives of 50 centers of the CML WP. A consensus was reached on the assessment of disease risk (EUTOS Long Term Survival [ELTS] score), on the definition of the most appropriate age boundaries for the choice of first-line treatment, on the choice of the TKI for first-line treatment, and on the definition of the responses that do not require a change of the TKI (BCR-ABL1 \u226410% at 3 months, \u22641% at 6 months, \u22640.1% at 12 months, \u22640.01% at 24 months), and of the responses that require a change of the TKI, when the goal is TFR (BCR-ABL1 &amp;gt;10% at 3 and 6 months, &amp;gt;1% at 12 months, and &amp;gt;0.1% at 24 months). These suggestions may help optimize the treatment strategy for TFR.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000865","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T17:26:07Z","timestamp":1577121967000},"page":"4280-4290","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP"],"prefix":"10.1182","volume":"3","author":[{"given":"Michele","family":"Baccarani","sequence":"first","affiliation":[{"name":"Universit\u00e0 di Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[{"name":"Universit\u00e0 La Sapienza Roma, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Accurso","sequence":"additional","affiliation":[{"name":"Policlinico Giaccone, Palermo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Bari, Bari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Annunziata","sequence":"additional","affiliation":[{"name":"Ospedale Cardarelli Napoli, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Barulli","sequence":"additional","affiliation":[{"name":"Ospedale San Salvatore, Pesaro, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germana","family":"Beltrami","sequence":"additional","affiliation":[{"name":"Policlinico San Martino, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Bergamaschi","sequence":"additional","affiliation":[{"name":"Policlinico San Martino, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Padova, Padua, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Siena, Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cagliari, Cagliari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Azienda Unit\u00e0 Sanitaria Locale\u2013Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) di Reggio Emilia, Reggio Emilia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cavazzini","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria (AOU) Arcispedale S. Anna Ferrara, Ferrara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cedrone","sequence":"additional","affiliation":[{"name":"AOU San Giovanni Addolorata, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cerrano","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugnola","sequence":"additional","affiliation":[{"name":"AOU Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"D\u2019Adda","sequence":"additional","affiliation":[{"name":"Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili, Brescia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Elena","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fazi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 La Sapienza Roma, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Fozza","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Sassari, Sassari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Pisa, Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Giai","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera (ASO) SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Gozzini","sequence":"additional","affiliation":[{"name":"AOU Careggi, Firenze, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gugliotta","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"La Barba","sequence":"additional","affiliation":[{"name":"Ospedale Civile Spirito Santo, Pescara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Levato","sequence":"additional","affiliation":[{"name":"AO Pugliese Ciaccio, Catanzaro, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lucchesi","sequence":"additional","affiliation":[{"name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Luciano","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lunghi","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Lunghi","sequence":"additional","affiliation":[{"name":"AOU Maggiore della Carit\u00e0, Novara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Malagola","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Brescia, Brescia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Ematologia Grande Ospedale, Reggio Calabria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Melpignano","sequence":"additional","affiliation":[{"name":"Ospedale A. Perrino, Brindisi, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Miggiano","sequence":"additional","affiliation":[{"name":"Ospedale San Bortolo, Vicenza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Montefusco","sequence":"additional","affiliation":[{"name":"AOU S. Andrea, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Musolino","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Messina, Messina, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera di Rilevo Nazionale (AORN) San Giuseppe (S.G.) Moscati, Avellino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pregno","sequence":"additional","affiliation":[{"name":"AOU Citt\u00e0 della Salute e della Scienza, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rapezzi","sequence":"additional","affiliation":[{"name":"ASO Croce e Carle, Cuneo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Rege-Cambrin","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Rupoli","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Ancona, Ancona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Salvucci","sequence":"additional","affiliation":[{"name":"Ospedale Santa Maria delle Croci, Ravenna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Sancetta","sequence":"additional","affiliation":[{"name":"ULSS3 Serenissima, Venice, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli\u2013IRCCS, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Spadano","sequence":"additional","affiliation":[{"name":"Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Catania, Catania, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Udine, Udine, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Tomassetti","sequence":"additional","affiliation":[{"name":"Ospedale degli Infermi, Rimini, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Trabacchi","sequence":"additional","affiliation":[{"name":"Azienda Unit\u00e0 Sanitaria Locale (AUSL) Ospedale Guglielmo di Saliceto, Piacenza, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Universit\u00e0 La Sapienza Roma, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Brescia, Brescia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Catania, Catania, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"issue":"14","key":"2020012213295465700_B1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"2020012213295465700_B2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"24","key":"2020012213295465700_B3","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2020012213295465700_B4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"2020012213295465700_B5","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2020012213295465700_B6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020012213295465700_B7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"35","key":"2020012213295465700_B8","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020012213295465700_B9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2020012213295465700_B10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2020012213295465700_B11","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"2020012213295465700_B12","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"2020012213295465700_B13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/asheducation-2013.1.168","article-title":"Which TKI? An embarrassment of riches for chronic myeloid leukemia patients","volume":"2013","author":"Hughes","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2020012213295465700_B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.23330","article-title":"Long-term safety and efficacy of imatinib mesylate (Gleevec\u00ae) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study","volume":"88","author":"Rousselot","year":"2013","journal-title":"Am J Hematol"},{"issue":"5","key":"2020012213295465700_B15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020012213295465700_B16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2020012213295465700_B17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","article-title":"Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib","volume":"124","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2020012213295465700_B18","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S2352-3026(15)00021-6","article-title":"Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol"},{"issue":"5","key":"2020012213295465700_B19","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"issue":"6","key":"2020012213295465700_B20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"issue":"18","key":"2020012213295465700_B21","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020012213295465700_B22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.24362","article-title":"Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia","volume":"91","author":"Gugliotta","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2020012213295465700_B23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/leu.2015.270","article-title":"Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2020012213295465700_B24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2020012213295465700_B25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020012213295465700_B26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020012213295465700_B27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.24591","article-title":"A population-based study of chronic myeloid leukemia patients treated with imatinib in first line","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am J Hematol"},{"issue":"11","key":"2020012213295465700_B28","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","article-title":"Treatment outcome in a population-based, \u201creal-world\u201d cohort of patients with chronic myeloid leukemia","volume":"102","author":"Geelen","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2020012213295465700_B29","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2020012213295465700_B30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"Hoffmann","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"2020012213295465700_B31","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00432-017-2385-7","article-title":"Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"143","author":"Hoffmann","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"2020012213295465700_B32","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/leu.2017.247","article-title":"Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results","volume":"31","author":"Hughes","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2020012213295465700_B33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2020012213295465700_B34","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 4","key":"2020012213295465700_B35","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"2020012213295465700_B36","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020012213295465700_B37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020012213295465700_B38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2020012213295465700_B39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020012213295465700_B40","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"2020012213295465700_B41","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer"},{"issue":"7","key":"2020012213295465700_B42","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2020012213295465700_B43","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","article-title":"Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan","volume":"103","author":"Takahashi","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"2020012213295465700_B44","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"2020012213295465700_B45","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Sau\u00dfele","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"2020012213295465700_B46","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/leu.2017.20","article-title":"Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence","volume":"31","author":"Baccarani","year":"2017","journal-title":"Leukemia"},{"issue":"14","key":"2020012213295465700_B47","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","volume":"124","author":"Rea","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"2020012213295465700_B48","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"key":"2020012213295465700_B49","author":"Linstone"},{"issue":"4","key":"2020012213295465700_B50","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"2020012213295465700_B51","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2020012213295465700_B52","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2020012213295465700_B53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2020012213295465700_B54","article-title":"The use of the EUTOS long-term survival score is strongly advised in elderly chronic myeloid leukemia patients [abstract]","volume":"132","author":"Castagnetti","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2020012213295465700_B55","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41375-018-0136-7","article-title":"Validation of the EUTOS long-term survival score in a recent independent cohort of \u201creal world\u201d CML patients","volume":"32","author":"Geelen","year":"2018","journal-title":"Leukemia"},{"issue":"26","key":"2020012213295465700_B56","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2020012213295465700_B57","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis [published correction appears in Blood. 2013;121(26):5259]","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2020012213295465700_B58","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann Hematol"},{"issue":"14","key":"2020012213295465700_B59","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","article-title":"Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2020012213295465700_B60","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/leu.2015.96","article-title":"Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors","volume":"29","author":"Wang","year":"2015","journal-title":"Leukemia"},{"issue":"22","key":"2020012213295465700_B61","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020012213295465700_B62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am J Hematol"},{"issue":"21","key":"2020012213295465700_B63","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2020012213295465700_B64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"2020012213295465700_B65","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2020012213295465700_B66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2020012213295465700_B67","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"22","key":"2020012213295465700_B68","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2020012213295465700_B69","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic response on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020012213295465700_B70","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3324\/haematol.2018.194522","article-title":"Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data","volume":"103","author":"Fassoni","year":"2018","journal-title":"Haematologica"},{"issue":"13","key":"2020012213295465700_B71","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib (50\u2009mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"2020012213295465700_B72","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3324\/haematol.2018.206797","article-title":"Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV","volume":"104","author":"Michel","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"2020012213295465700_B73","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3324\/haematol.2018.214445","article-title":"Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?","volume":"104","author":"Saglio","year":"2019","journal-title":"Haematologica"},{"issue":"19","key":"2020012213295465700_B74","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.29512","article-title":"Are high drug prices for hematologic malignancies justified? A critical analysis","volume":"121","author":"Chhatwal","year":"2015","journal-title":"Cancer"},{"issue":"7","key":"2020012213295465700_B75","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2020012213295465700_B76","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","article-title":"Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study","volume":"6","author":"Shih","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"2020012213295465700_B77","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2020012213295465700_B78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2020012213295465700_B79","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2020012213295465700_B80","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2020012213295465700_B81","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"issue":"21","key":"2020012213295465700_B82","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2015-06-641043","article-title":"Is there a best TKI for chronic phase CML?","volume":"126","author":"Larsson","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2020012213295465700_B83","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.24249","article-title":"Chronic myeloid leukemia: first-line drug of choice","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2020012213295465700_B84","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.24247","article-title":"Chronic myeloid leukemia: Second-line drugs of choice","volume":"91","author":"Gambacorti-Passerini","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"2020012213295465700_B85","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2020012213295465700_B86","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2020012213295465700_B87","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase","volume":"141","author":"Machova Polakova","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16","key":"2020012213295465700_B88","doi-asserted-by":"crossref","first-page":"21982","DOI":"10.18632\/oncotarget.8010","article-title":"Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients","volume":"7","author":"Soverini","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"2020012213295465700_B89","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2016.145888","article-title":"Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia","volume":"101","author":"Baer","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"2020012213295465700_B90","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"2020012213295465700_B91","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","article-title":"Management of pregnant chronic myeloid leukemia patients","volume":"9","author":"Abruzzese","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"2020012213295465700_B92","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2017.77.2574","article-title":"Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy","volume":"36","author":"Berman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020012213295465700_B93","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood-2018-99-118925","article-title":"International prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission in patients with chronic myeloid leukemia. A GIMEMA and HOVON study. 60th Annual Meeting of the American Society of Hematology [abstract]","volume":"132","author":"Pane","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2020012213295465700_B94","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/S2352-3026(19)30112-7","article-title":"The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia","volume":"6","author":"Andrews","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/24\/4280\/1549956\/advancesadv2019000865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/24\/4280\/1549956\/advancesadv2019000865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T18:30:18Z","timestamp":1579717818000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/24\/4280\/429987\/Managing-chronic-myeloid-leukemia-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":94,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000865","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]}}}